Memorial Day Offer

Discover your mystery discount!

Eugeroic

Characteristics of Eugeroics: – Promote wakefulness and alertness – Medically indicated for certain sleep disorders – Prescribed off-label for idiopathic hypersomnia – Have lower addictive […]

« Back to Glossary Index

Characteristics of Eugeroics:
– Promote wakefulness and alertness
– Medically indicated for certain sleep disorders
– Prescribed off-label for idiopathic hypersomnia
– Have lower addictive potential compared to classical psychostimulants
– Include modafinil, armodafinil, adrafinil, solriamfetol, and pitolisant

Recent Research on Eugeroics:
– Cephalon developing successors to prototypical eugeroic
– Compound fluorenol induces greater wakefulness than modafinil
– All marketed eugeroics classified as CNS stimulants
– Future developments expected to further distinguish eugeroics from classical stimulants
– CE-123 under patent by Red Bull

References on Eugeroics:
– Studies on adrafinil, modafinil, and armodafinil
– Prescribing information by the FDA for Provigil and Nuvigil
– Practice parameters for the treatment of narcolepsy and hypersomnias
– Reviews on the neuropharmacology of bupropion
– Clinical trials and assessments of pitolisant for narcolepsy treatment

Mechanism of Action of Eugeroics:
– Modafinil and armodafinil act as weak dopamine reuptake inhibitors
– Adrafinil acts as a prodrug for modafinil
– Solriamfetol acts as a norepinephrine-dopamine reuptake inhibitor
– Pitolisant acts as a histamine 3 receptor antagonist/inverse agonist
– Different eugeroics have varying mechanisms of action

Future Developments in Eugeroics:
– Potential advancements to distinguish eugeroics from traditional CNS stimulants
– Research on next-generation modafinil-like compounds
– Studies on novel waking drugs like solriamfetol and pitolisant
– Development of orexin type-2 receptor agonists for narcolepsy treatment
– Use of sulfoxides for improving cognitive function and treating substance addictions

Eugeroic (Wikipedia)

Eugeroics (originally "eugrégorique" or "eugregoric"), also known as wakefulness-promoting agents and wakefulness-promoting drugs, are a class of drugs that promote wakefulness and alertness. They are medically indicated for the treatment of certain sleep disorders including excessive daytime sleepiness (EDS) in narcolepsy or obstructive sleep apnea (OSA). Eugeroics are also often prescribed off-label for the treatment of EDS in idiopathic hypersomnia. In contrast to classical psychostimulants, such as methylphenidate and amphetamine, which are also used in the treatment of these disorders, eugeroics typically do not produce marked euphoria, and, consequently, have a lower addictive potential.

Eugeroic
Drug class
The chemical structure of modafinil, the prototypical drug of this class
Class identifiers
SynonymsWakefulness-promoting agent
Wakefulness-promoting drug
UsePromote wakefulness and alertness
ATC codeN06B
Legal status
In Wikidata

Modafinil and armodafinil are each thought to act as selective, weak, atypical dopamine reuptake inhibitors (DRI), whereas adrafinil acts as a prodrug for modafinil. Other eugeroics include solriamfetol, which acts as a norepinephrine–dopamine reuptake inhibitor (NDRI), and pitolisant, which acts as a histamine 3 (H3) receptor antagonist/inverse agonist.

« Back to Glossary Index
This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.